Compare VF Corp (VFC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VF Corp vs State Street SPDR S&P Biotech ETF — how do they compare? VF Corp trades at $14.59 (market cap $5.81B), while State Street SPDR S&P Biotech ETF trades at $159.43. The key difference: VF Corp pays a 2.44% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, VF Corp nearer its low. Which is the better fit depends on your goals.
| VFC | XBI | |
|---|---|---|
Market Cap | $5.81B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $21.55 | $164.28 |
52-Week Low | $12.21 | $86.92 |
Enterprise Value | $10.09B | — |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VFC trades at $14.90, down 0.6% on the day, near the low end of analyst targets. Technical indicators are bearish, with mixed recent earnings showing a Q4 beat but Q1 and Q2 misses. Revenue has declined from $11.8B in 2022 to $9.5B in 2025, with net losses in 2024 and 2025, though 2026 projects a return to profitability. The company faces brand-specific headwinds, particularly with Vans, while maintaining a reasonable P/S ratio of 0.62.
The outlook is cautious. Deleveraging progress and a raised 2027 revenue outlook offer some optimism, but persistent Vans weakness and macro pressures pose significant risks. Analyst consensus is Hold, with a $17.44 price target suggesting limited upside from current levels amid ongoing operational challenges.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
